Screening of female family members of von Willebrand disease patients: utility of a modified screening tool in a high-risk population

被引:3
|
作者
Faiz, A. S. [1 ]
Kaveney, A. [1 ]
Guo, S. [1 ]
Murphy, S. [2 ]
Philipp, C. S. [1 ]
机构
[1] Rutgers Robert Wood Johnson Med Sch, Div Hematol, New Brunswick, NJ 08854 USA
[2] Rutgers Canc Inst New Jersey, Dept Pediat Hematol Oncol, New Brunswick, NJ USA
关键词
bleeding symptoms; inherited bleeding disorder; screening tool; von Willebrand disease; von Willebrand factor; HEMOPHILIA TREATMENT CENTERS; MENSTRUAL BLOOD-LOSS; BLEEDING SYMPTOMS; UNITED-STATES; DIAGNOSIS; TYPE-1; VWD; MULTICENTER; PREVALENCE; MANAGEMENT;
D O I
10.1111/hae.13188
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Family members of Von Willebrand disease (VWD) patients may have low levels of VWF without major bleeding episodes and often remain undiagnosed. Aim: The purpose of this study was to assess the utility of a modified Screening Tool in identifying previously untested reproductive age female family members of VWD patients for haemostatic evaluation. Methods: Ninety-four reproductive age women including 41 previously untested family members of VWD patients, 26 previously diagnosed VWD patients and 27 healthy controls were administered a modified Screening Tool and had blood drawn for CBC, ferritin, and VWF testing. Participants completed a pictorial blood assessment chart (PBAC) with menses. Results: The modified Screening Tool was positive in 32% family members, 77% VWD patients, and 19% controls (P < 0.001). Combined with low ferritin, the modified Screening Tool was positive in 66% family members, 92% VWD patients, and 44% controls (P = 0.001). In family members, incorporating low ferritin with the modified Screening Tool resulted in a sensitivity of 86% (95% CI, 42-100) and negative predictive value of 93% (95% CI, 66-100). In the control group, NPV was between 92% and 95% for the modified Screening Tool and also for the modified Screening Tool combined with low ferritin or a positive PBAC. Conclusion: These data in a racially diverse population suggest the usefulness of a simple, easy to administer modified Screening Tool. In conjunction with ferritin it could be used in a primary care setting to stratify reproductive age women with a family history of VWD for haemostatic evaluation.
引用
收藏
页码:736 / 742
页数:7
相关论文
共 50 条
  • [41] Evaluation of an IgM/IgG Sensitive Enzyme Immunoassay and the Utility of Index Values for the Screening of Syphilis Infection in a High-Risk Population
    Wong, Ernest H.
    Klausner, Jeffrey D.
    Caguin-Grygiel, Gloria
    Madayag, Carmela
    Barber, Kim O.
    Qiu, Julia S.
    Liska, Sally
    Pandori, Mark W.
    SEXUALLY TRANSMITTED DISEASES, 2011, 38 (06) : 528 - 532
  • [42] Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population
    Kaplan, David J.
    Boorjian, Stephen A.
    Ruth, Karen
    Egleston, Brian L.
    Chen, David Y. T.
    Viterbo, Rosalia
    Uzzo, Robert G.
    Buyyounouski, Mark K.
    Raysor, Susan
    Giri, Veda N.
    BJU INTERNATIONAL, 2010, 105 (03) : 334 - 337
  • [43] High-risk screening for Anderson-Fabry disease in patients with cardiac, renal, or neurological manifestations
    Nakagawa, Naoki
    Sawada, Jun
    Sakamoto, Naka
    Takeuchi, Toshiharu
    Takahashi, Fumihiko
    Maruyama, Jun-ich
    Momosaki, Ken
    Nakamura, Kimitoshi
    Endo, Fumio
    Hasebe, Naoyuki
    JOURNAL OF HUMAN GENETICS, 2019, 64 (09) : 891 - 898
  • [44] Determining common variants in patients with haemophilia A in South Vietnam and screening female carriers in their family members
    Bang Suong Thi Nguyen
    Xuan Thao Thi Le
    Nghia Huynh
    Huy Huu Nguyen
    Cong-Minh Truong Nguyen
    Bac Hoang Nguyen
    JOURNAL OF CLINICAL PATHOLOGY, 2023, 76 (05) : 339 - 344
  • [45] Fabry disease screening in high-risk populations in Japan: a nationwide study
    Yoshida, Shinichiro
    Kido, Jun
    Sawada, Takaaki
    Momosaki, Ken
    Sugawara, Keishin
    Matsumoto, Shirou
    Endo, Fumio
    Nakamura, Kimitoshi
    ORPHANET JOURNAL OF RARE DISEASES, 2020, 15 (01)
  • [46] Celiac Disease Screening for High-Risk Groups: Are We Doing It Right?
    Kumral, Dennis
    Syed, Sana
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (08) : 2187 - 2195
  • [47] Glaucoma Screening and Referral Risk Factors in a High-Risk Population: Follow-Up Study of the Manhattan Vision Screening Study
    Wang, Qing
    Valenzuela, Ives A.
    Harizman, Noga
    Gorroochurn, Prakash
    Torres, Desiree R.
    Maruri, Stefania C.
    Diamond, Daniel F.
    Horowitz, Jason D.
    Friedman, David S.
    De Moraes, C. Gustavo
    Cioffi, George A.
    Liebmann, Jeffrey M.
    Hark, Lisa A.
    JOURNAL OF GLAUCOMA, 2025, 34 (03) : 164 - 174
  • [48] Can the Boston Carpal Tunnel Syndrome Questionnaire Be Used as a Screening Tool Among a Potentially High-Risk Population in Singapore?
    Sirisena, Dinesh
    Lim, Ivan
    Sim, Shauna
    Tong, Pei-Yein
    Rajaratnam, Vaikunthan
    JOURNAL OF HAND AND MICROSURGERY, 2022, 14 (01) : 39 - 46
  • [49] Generation and optimization of the self-administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease
    Casey, Lara J.
    Tuttle, Angie
    Grabell, Julie
    Hopman, Wilma
    Moorehead, Paul C.
    Blanchette, Victor S.
    Wu, John K.
    Steele, MacGregor
    Klaassen, Robert J.
    Silva, Mariana
    Rand, Margaret L.
    James, Paula D.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (10)
  • [50] Adherence to, and outcomes of, a galactomannan screening protocol in high-risk hematology patients
    Harricharan, S.
    Biederman, K.
    Bombassaro, A. M.
    Lazo-Langner, A.
    Elsayed, S.
    Fulford, A.
    Delport, J. A.
    Xenocostas, A.
    CURRENT ONCOLOGY, 2018, 25 (02) : E139 - E145